BrainGate2 System for Quadriplegia
(BG-Speech-01 Trial)
Trial Summary
What is the purpose of this trial?
The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with their thoughts.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it excludes those on chronic steroids or immunosuppressive therapy. It's best to discuss your specific medications with the study team.
What data supports the effectiveness of the BrainGate2 treatment for quadriplegia?
Research shows that the BrainGate2 system allows people with paralysis to control devices like tablets and computers using their brain signals, demonstrating its potential to improve daily life activities. Additionally, similar brain-computer interfaces have been used to restore hand function and enable walking in individuals with spinal cord injuries, indicating the effectiveness of such systems in restoring movement and control.12345
Is the BrainGate2 System safe for humans?
The BrainGate feasibility study, which is the largest and longest-running clinical trial of an implanted brain-computer interface, provides safety data for the BrainGate Neural Interface System. Although the study focuses on people with paralysis, it offers valuable insights into the safety of chronically implanted microelectrode arrays in humans.678910
How is the BrainGate2 treatment unique for quadriplegia?
The BrainGate2 treatment is unique because it uses a brain-computer interface (BCI) that directly connects with the nervous system to read motor intentions from the brain, allowing people with quadriplegia to control devices like tablets and prosthetics with their thoughts. This approach is different from traditional treatments as it provides a direct neural link to restore function and independence.25101112
Research Team
Jaimie Henderson, MD
Principal Investigator
Stanford University
Eligibility Criteria
This trial is for adults aged 18-80 with tetraplegia due to conditions like ALS, spinal cord injury, or stroke. They must be unable to speak clearly or at all but have one reliable way to communicate. Participants should live within a three-hour drive of the study site and are expected to survive more than six months.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Implantation and Initial Testing
Placement of the BrainGate2 sensor(s) into the speech-related cortex and initial testing of the system
Post-Implant Evaluation
Participants are monitored for device safety and feasibility of using the BrainGate system for communication
Long-term Follow-up
Participants are monitored for long-term safety and effectiveness of the device
Treatment Details
Interventions
- BrainGate Neural Interface System (Neural Interface System)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Leigh R. Hochberg, MD, PhD.
Lead Sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
Collaborator